Gala Therapeutics

OverviewSuggest Edit

Gala Therapeutics is a medical device company developing technologies for the treatment of pulmonary diseases. It offers RheOx, a system comprised of a single-use catheter and an electrosurgical generator. The system is used to deliver non-thermal energy to the airways to reduce mucus-producing cells in patients with Chronic Bronchitis.
TypePrivate
Founded2015
HQMenlo Park, CA, US
Websitegalatherapeutics.com

Latest Updates

Employees (est.) (Jul 2021)37(+6%)
Cybersecurity ratingDMore

Gala Therapeutics Office Locations

Gala Therapeutics has an office in Menlo Park
Menlo Park, CA, US (HQ)
155 Jefferson Dr #100
Show all (1)

Gala Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2015

Gala Therapeutics total Funding

$70 m

Gala Therapeutics latest funding size

$42.5 m

Time since last funding

2 years ago
Gala Therapeutics's latest funding round in November 2019 was reported to be $42.5 m. In total, Gala Therapeutics has raised $70 m
Show all financial metrics

Gala Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

D

67/100

SecurityScorecard logo

Gala Therapeutics Online and Social Media Presence

Embed Graph

Gala Therapeutics Blogs

Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis

SAN CARLOS, Calif., May 20, 2021 /PRNewswire/ — Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx™ Bronchial Rheoplasty System for the treatment of the symptoms of chronic bronchitis....

Doug Godshall to Chair Gala Therapeutics Board of Directors

San Carlos, CA, March 2, 2021 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat chronic bronchitis and other pulmonary diseases, announced today that it has appointed Douglas Godshall to chair of its Board of Directors....

Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOxTM System for Chronic Bronchitis

San Carlos, CA – Feb. 22, 2021 – Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announces U.S. Food and Drug Administration (FDA) conditional Investigational Device Exemption (IDE) approval to commence its pivotal clinical trial called RheSolve,...

Gala Therapeutics Frequently Asked Questions

  • When was Gala Therapeutics founded?

    Gala Therapeutics was founded in 2015.

  • How many employees does Gala Therapeutics have?

    Gala Therapeutics has 37 employees.

  • Who are Gala Therapeutics competitors?

    Competitors of Gala Therapeutics include Magstim, Lungpacer Medical and Inspire Medical Systems.

  • Where is Gala Therapeutics headquarters?

    Gala Therapeutics headquarters is located at 155 Jefferson Dr #100, Menlo Park.

  • Where are Gala Therapeutics offices?

    Gala Therapeutics has an office in Menlo Park.

  • How many offices does Gala Therapeutics have?

    Gala Therapeutics has 1 office.